This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxygen Biotherapeutics Reports Financial Results For The Third Quarter FY2013

Research and Development expenses were $1,611,293 for the nine months ended January 31, 2013, compared to $4,883,903 for the same period in the prior year. The decrease for the period was due primarily to reductions in costs incurred for personnel, consultants, facilities and other general expenses; partially offset by an increase in costs associated with clinical and preclinical development of Oxycyte.

As of January 31, 2013, the Company had cash and cash equivalents totaling $828,811 compared to $1,879,872 at April 30, 2012.

Conference Call

Management will host a conference call and webcast regarding the third quarter financial results for the three and nine months ending January 31, 2013, on Tuesday, March 19, 2013, at 11 a.m. ET. To access the live teleconference dial (866) 277-1184 (U.S. and Canada), or (617) 597-5360 (international.) The participant pass code is 10084976. Also, a live webcast will be available on our web site http://www.oxybiomed.com/investors.htm . A replay of the webcast will be available by phone or on the Oxygen website for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international). The pass code for the replay is 10065352.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte ® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based oxygen-carrying creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the company has commercialized its Dermacyte ® line of oxygen-rich skin care products for the anti-aging market.

Financial Tables Follow

The accompanying notes found in the company’s Form 10-Q filed with the SECon March 18, 2013 are an integral part of these Financial Statements.
 
 

OXYGEN BIOTHERAPEUTICS, INC.

(a development stage enterprise)

BALANCE SHEETS

(unaudited)
         
January 31, 2013 April 30, 2012
(Unaudited)  
 
ASSETS
Current assets
Cash and cash equivalents $ 828,811 $ 1,879,872
Accounts receivable 13,642 13,385
Government grant receivable 87,185 35,650
Inventory 107,938 83,370
Prepaid expenses 341,884 455,946
Other current assets   272,713     162,809  
Total current assets 1,652,173 2,631,032
Property and equipment, net 226,808 293,606
Debt issuance costs, net 182,197 278,659
Intangible assets, net 923,397 872,971
Other assets   58,262     65,666  
Total assets $ 3,042,837   $ 4,141,934  
 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable $ 807,679 $ 542,809
Accrued liabilities 1,085,373 1,273,837
Convertible preferred stock - 1,247,266
Current portion of notes payable, net   98,657     62,958  
Total current liabilities 1,991,709 3,126,870
Other liabilities 65,592 -
Long-term portion of notes payable, net   2,586,109     1,361,110  
Total liabilities 4,643,410 4,487,980
 
 
Commitments and contingencies; see Note 7.
Stockholders' deficit
Preferred stock, undesignated, authorized 9,992,500 shares; see Note 5. - -

Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued

and outstanding 33,650,499 and 29,417,718, respectively
3,365 2,942
Additional paid-in capital 113,581,120 107,279,296
Deficit accumulated during the development stage   (115,185,058 )   (107,628,284 )
Total stockholders’ deficit   (1,600,573 )   (346,046 )
Total liabilities and stockholders' deficit $ 3,042,837   $ 4,141,934  
 
 

OXYGEN BIOTHERAPEUTICS, INC.

(a development stage enterprise)

STATEMENTS OF OPERATIONS

(unaudited)
 
 
             
 

Period from May 26,

1967 (Inception) to
Three months ended January 31, Nine months ended January 31,

January 31, 2013
2013   2012 2013       2012
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited)
Product revenue $ 499,153 $ 2,871 $ 4,673 $ 28,899 $ 91,565
Cost of sales   326,046     1,534     2,512     16,578     47,616  
Net product revenue 173,107 1,337 2,161 12,321 43,949
Government grant revenue   1,311,550     221,051     146,101     997,035     224,345  
Total net revenue 1,484,657 222,388 148,262 1,009,356 268,294
 
Operating expenses
Selling, general, and administrative 50,036,200 1,441,500 1,422,103 3,127,133 4,883,903
Research and development 23,686,605 369,447 599,935 1,611,293 1,740,473
Restructuring expense 220,715 2,941 - 220,715 -
Loss on impairment of long-lived assets   363,691     -     -     -     -  
Total operating expenses 74,307,211 1,813,888 2,022,038 4,959,141 6,624,376
 
Net operating loss 72,822,554 1,591,500 1,873,776 3,949,785 6,356,082
 
Interest expense 43,338,767 821,777 5,341,988 3,615,204 6,649,554
Loss on extinguishment of debt 250,097 - - - -
Other (income) expense   (1,226,360 )   (323 )   82,850     (8,215 )   91,970  
Net loss $ 115,185,058   $ 2,412,954   $ 7,298,614   $ 7,556,774   $ 13,097,606  
 
Net loss per share, basic $ (0.07 ) $ (0.26 ) $ (0.24 ) $ (0.53 )
Weighted average number of common shares outstanding, basic 33,177,893 27,558,532 31,828,750 24,922,512
Net loss per share, diluted $ (0.14 ) $ (0.39 ) $ (0.30 ) $ (0.65 )
Weighted average number of common shares outstanding, diluted 35,352,784 29,731,481 34,003,641 26,630,311
 

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and Dermacyte product lines and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 15, 2011 and in our subsequent filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,549.47 -93.54 -0.56%
S&P 500 1,976.75 -12.12 -0.61%
NASDAQ 4,801.3010 -27.0240 -0.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs